HIX small business plans 7% cheaper on average

| | Health Exec | Economics

Health plans available to small businesses in health insurance exchanges are on average about 7 percent cheaper than comparable plans offered elsewhere, reports The Washington Post.

The newspaper cites an analysis conducted by a team of researchers at the National Opinion Research Center at the University of Chicago.

“It’s definitely surprising,” said Jon Gabel, a senior fellow at the center, noting that many insurers had expressed disinterest in selling plans on the SHOP exchanges. “So, I expected them to price those plans higher than the plans sold off the SHOP, but it didn’t turn out that way—in fact, just the opposite.”

Read more below:

 

 

Obamacare’s small business exchanges offer cheaper health coverage, study shows

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.